Dr. Stacy A. Mandras, MD
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- University of Maryland School of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 180
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Maryland School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
FL license ME144091 · LA license MD.203226 -
Cardiovascular Disease Physician
LA license MD.203226 · MO license 2006015684
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Adventhealth Orlando Orlando, FL
- Adventhealth Sebring Sebring, FL
Medical groups
- Florida Hospital Medical Group Inc (1,755 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 180
- Services billed
- 626
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 192 | 47 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 106 | 98 |
| Established patient office or other outpatient visit, 40-54 minutes | 74 | 41 |
| Test for exercise-induced lung stress | 44 | 30 |
| New patient office or other outpatient visit, 60-74 minutes | 28 | 28 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 27 | 27 |
| Established patient office or other outpatient visit, 30-39 minutes | 21 | 19 |
| Heart muscle strain imaging | 18 | 18 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 16 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Adempas (riociguat) | 102 |
| Tyvaso Dpi (treprostinil) | 92 |
| Opsumit (macitentan) | 69 |
| Tadalafil | 52 |
| Ambrisentan | 49 |
| Warfarin Sodium Other prescribers in Orlando, FL | 49 |
| Spironolactone Other prescribers in Orlando, FL | 48 |
| Rosuvastatin Calcium Other prescribers in Orlando, FL | 37 |
| Uptravi (selexipag) | 34 |
| Amlodipine Besylate Other prescribers in Orlando, FL | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 13 payments worth $2,424 in total to this clinician.
| Cvrx, Inc. | $1,838 |
|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $200 |
| Actelion Pharmaceuticals US, Inc. | $180 |
| Abbott Laboratories | $155 |
| Edwards Lifesciences Corporation | $28.51 |
| Briohealth Solutions, Inc. | $21.57 |
| Consulting Fee | $1,900 |
|---|---|
| Food and Beverage | $524 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Cvrx, Inc. Apr 29, 2025 | Consulting Fee Barostim Neo System · Heart Failure and Hypertension | $1,700 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 30, 2025 | Consulting Fee Adempas · Cardio-pulmonary | $200 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $266,133 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Hea…
Merck Sharp & Dohme LLC - A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserv…
Merck Sharp & Dohme LLC - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
United Therapeutics Corporation · Enrolling by invitation · NCT03683186 - A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
United Therapeutics Corporation · Completed · NCT03626688 - BAY 632521, RiOciguAt UseRs Registry The ROAR registry
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.